Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines

Caldeira, Jerri C.; Perrine, Michael; Pericle, Federica; Cavallo, Federica

doi:10.3390/v12050488

Cited by 49 publications

(41 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…retroviridae ) present an envelope composed of an external lipidic membrane acquired while budding from the host cell surface [ 69 ]. As VLPs contain non-self proteins and potential pathogen-associated molecular patterns, they can be immunogenic and were mostly assessed as anti-cancer immuno-stimulatory treatments [ 70 ]. Their use as vaccines showed a good safety profile that makes them suitable for future use as nanovectors.…”

Section: Types Of Nanovectorsmentioning

confidence: 99%

Delivery of cancer therapies by synthetic and bio-inspired nanovectors

et al. 2021

View full text Add to dashboard Cite

Background As a complement to the clinical development of new anticancer molecules, innovations in therapeutic vectorization aim at solving issues related to tumor specificity and associated toxicities. Nanomedicine is a rapidly evolving field that offers various solutions to increase clinical efficacy and safety. Main Here are presented the recent advances for different types of nanovectors of chemical and biological nature, to identify the best suited for translational research projects. These nanovectors include different types of chemically engineered nanoparticles that now come in many different flavors of ‘smart’ drug delivery systems. Alternatives with enhanced biocompatibility and a better adaptability to new types of therapeutic molecules are the cell-derived extracellular vesicles and micro-organism-derived oncolytic viruses, virus-like particles and bacterial minicells. In the first part of the review, we describe their main physical, chemical and biological properties and their potential for personalized modifications. The second part focuses on presenting the recent literature on the use of the different families of nanovectors to deliver anticancer molecules for chemotherapy, radiotherapy, nucleic acid-based therapy, modulation of the tumor microenvironment and immunotherapy. Conclusion This review will help the readers to better appreciate the complexity of available nanovectors and to identify the most fitting “type” for efficient and specific delivery of diverse anticancer therapies.

show abstract

Section: Types Of Nanovectorsmentioning

confidence: 99%

Delivery of cancer therapies by synthetic and bio-inspired nanovectors

et al. 2021

View full text Add to dashboard Cite

show abstract

“…When expressed in E. coli , this recombinant protein self-assembles into a VLP [ 37 ]. Because of its multivalence and small size, the VLP is strongly immunogenic, as we have extensively discussed in [ 38 ]. The presentation of epitopes in a dense repetitive array is highly stimulatory to B-cells, and the nano-size of the particle enhances its uptake by antigen-presenting cells [ 39 ].…”

Section: Introductionmentioning

confidence: 99%

“…VLP-based vaccines are already licensed for infectious diseases and cancer-correlated pathogens [ 41 , 42 ], thus AX09 presents a high translational value. Of note, AX09 represents a novelty in the VLP family of vaccines, as no VLP targeting cancer antigens has been approved for use in the clinic so far [ 38 , 41 , 42 ].…”

Section: Introductionmentioning

confidence: 99%

Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer

Rolih

Caldeira²,

Bolli

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Metastatic breast cancer (MBC) is the leading cause of cancer death in women due to recurrence and resistance to conventional therapies. Thus, MBC represents an important unmet clinical need for new treatments. In this paper we generated a virus-like particle (VLP)-based vaccine (AX09) to inhibit de novo metastasis formation and ultimately prolong the survival of patients with MBC. To this aim, we engineered the bacteriophage MS2 VLP to display an extracellular loop of xCT, a promising therapeutic target involved in tumor progression and metastasis formation. Elevated levels of this protein are observed in a high percentage of invasive mammary ductal tumors including triple negative breast cancer (TNBC) and correlate with poor overall survival. Moreover, xCT expression is restricted to only a few normal cell types. Here, we tested AX09 in several MBC mouse models and showed that it was well-tolerated and elicited a strong antibody response against xCT. This antibody-based response resulted in the inhibition of xCT’s function in vitro and reduced metastasis formation in vivo. Thus, AX09 represents a promising novel approach for MBC, and it is currently advancing to clinical development.

show abstract

“…When the VLP germinates, it uses the lipid bilayer membrane of the host cell to encapsulate some viral structural proteins. VLP is very similar to the real virus in morphology and structure but does not contain the genome of the virus and is neither proliferative nor infectious [ 14 , 15 ]. In addition to the formation of VLPs during the propagation of viruses in infected cells, VLPs can also be constructed artificially by expressing the necessary viral proteins in cell culture, laying the foundation for the development of VLP vaccines.…”

Section: Introductionmentioning

confidence: 99%

Identification of the Functional Domain of HPIV3 Matrix Protein Interacting with Nucleocapsid Protein

Deng

Zhang

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Human parainfluenza virus type 3 (HPIV3) is the main pathogen that causes respiratory infections in infants, young children, and the elderly. Currently, there are no vaccines and effective anti-infective drugs. Studying the replication and proliferation mechanism of HPIV3 is helpful for exploring the targets of anti-HPIV3 infection. Matrix protein (M) and nucleocapsid protein (N) are two key structural proteins of HPIV3 that exert important functions in HPIV3 proliferation. Herein, we aim to clarify the functional domains of M and N interaction. HPIV3 M and N expression plasmids of pCAGGS-HA-M and pCAGGS-N-Myc/Flag, M C-terminal truncation mutant plasmids of pCAGGSHA-MΔC120, MΔC170, MΔC190, and MΔC210, and M C-terminal plasmid of pCAGGS-HA-MC190 and C-terminal deletion mutant plasmid of pCAGGS-MΔN143-182 were constructed. By using immunoprecipitation, immunofluorescence, and virus-like particle (VLP) germination experiments, we found that N was encapsulated into M-mediated VLP through N and M interaction. Moreover, the C-terminus of the M played a key role in the interaction between M and N. The C-terminus of the M encapsulated the N into the VLP. We finally determined that the 143-182 amino acids in the M were the functional regions that encapsulated the N into the M-mediated VLP. Our findings confirmed the interaction between M and N and for the first time clarified that the 143-182 amino acid region in M was the functional region that interacted with N, which provides a molecular basis for exploring effective anti-HPIV3 targets.

show abstract

Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines

Cited by 49 publications

References 105 publications

Delivery of cancer therapies by synthetic and bio-inspired nanovectors

Delivery of cancer therapies by synthetic and bio-inspired nanovectors

Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer

Identification of the Functional Domain of HPIV3 Matrix Protein Interacting with Nucleocapsid Protein

Contact Info

Product

Resources

About